{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:45:31Z","timestamp":1791978331821,"version":"4.4.0"},"reference-count":150,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["T32ES007091"],"award-info":[{"award-number":["T32ES007091"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>The US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA) guidances on small\u2010molecule drug\u2013drug interactions (DDIs), with input from the International Transporter Consortium (ITC), recommend the evaluation of nine drug transporters. Although other clinically relevant drug uptake and efflux transporters have been discussed in ITC white papers, they have been excluded from further recommendation by the ITC and are not included in current regulatory guidances. These include the ubiquitously expressed equilibrative nucleoside transporters (ENT) 1 and ENT2, which have been recognized by the ITC for their potential role in clinically relevant nucleoside analog drug interactions for patients with cancer. Although there is comparatively limited clinical evidence supporting their role in DDI risk or other adverse drug reactions (ADRs) compared with the nine highlighted transporters, several <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> studies have identified ENT interactions with non\u2010nucleoside\/non\u2010nucleotide drugs, in addition to nucleoside\/nucleotide analogs. Some noteworthy examples of compounds that interact with ENTs include cannabidiol and selected protein kinase inhibitors, as well as the nucleoside analogs remdesivir, EIDD\u20101931, gemcitabine, and fialuridine. Consequently, DDIs involving the ENTs may be responsible for therapeutic inefficacy or off\u2010target toxicity. Evidence suggests that ENT1 and ENT2 should be considered as transporters potentially involved in clinically relevant DDIs and ADRs, thereby warranting further investigation and regulatory consideration.<\/jats:p>","DOI":"10.1002\/cpt.2984","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T14:18:56Z","timestamp":1688566736000},"page":"780-794","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Addressing the Clinical Importance of Equilibrative Nucleoside Transporters in Drug Discovery and Development"],"prefix":"10.1111","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-8388","authenticated-orcid":false,"given":"Raymond K.","family":"Hau","sequence":"first","affiliation":[{"name":"Department of Pharmacology &amp; Toxicology, College of Pharmacy The University of Arizona  Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Physiology, College of Medicine The University of Arizona  Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-8140","authenticated-orcid":false,"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Toxicology, College of Pharmacy The University of Arizona  Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"e_1_2_11_1_1","unstructured":"US Food and Drug Administration.In vitrodrug interaction studies \u2014 cytochrome P450 enzyme\u2010 and transporter\u2010mediated drug interactions guidance for industry<https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/in\u2010vitro\u2010drug\u2010interaction\u2010studies\u2010cytochrome\u2010p450\u2010enzyme\u2010and\u2010transporter\u2010mediated\u2010drug\u2010interactions> (2020). Accessed February 5 2023."},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.74"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2644"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1112"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3028"},{"key":"e_1_2_11_6_1","unstructured":"European Medicines Agency.Guideline on the investigation of drug interactions<https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010investigation\u2010drug\u2010interactions\u2010revision\u20101_en.pdf> (2013). Accessed February 5 2023."},{"key":"e_1_2_11_7_1","unstructured":"Pharmaceuticals and Medical Devices Agency.Guideline on drug interaction for drug development and appropriate provision of information<https:\/\/www.pmda.go.jp\/files\/000228122.pdf> (2019). Accessed February 5 2023."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.354"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511232103"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2293"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13292"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2196"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.121.000333"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-003-1103-2"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20160038"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2012.05.007"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b01189"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00941"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.20.452"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250600861751"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12111005"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07208.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp200129p"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp3004308"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.45.28423"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0197-89"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(00)00555-2"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.236117"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-7646(98)80047-2"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3280739"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.090720"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000423"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.120.000169"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00374155"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00293.2007"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203265"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-016-3306-5"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-019-0245-7"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2003.09.018"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M701735200"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crstbi.2022.05.005"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/2472555219870123"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410348200"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M105324200"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.46.30818"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M307938200"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M513825200"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201500433"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00542.2007"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00007.2007"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00215.2002"},{"key":"e_1_2_11_52_1","first-page":"G1314","article-title":"Sodium\u2010dependent nucleoside transport in the human intestinal brush\u2010border membrane","volume":"272","author":"Patil S.D.","year":"1997","journal-title":"Am.\u00a0J.\u00a0Physiol."},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.1998.274.2.G261"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2736(99)00045-0"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-015-3118-z"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.118.083329"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00207-0"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0457OC"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1373"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-228551"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.3665"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050177"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03312.x"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.076356"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.034611"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.071837"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/15257770.2016.1210805"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90672.2008"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2017.10.011"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-021-00703-2"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.028654"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-014-0437-y"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.09.005"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.10.062"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0337"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.044214"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.741074"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.12.8375"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2009.00897.x"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(83)90006-8"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(84)90548-0"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.831"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10040246"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800415)45:8<2009::AID-CNCR2820450805>3.0.CO;2-A"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0378(98)00056-4"},{"issue":"1","key":"e_1_2_11_86_1","first-page":"S33","article-title":"Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir","volume":"14","author":"Kiessling A.A.","year":"1998","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00604-5"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04444-w"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.015768"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2014.11.005"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.534"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.145854"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1826"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088818"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2010.01.011"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2019.11.008"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121521"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.08.076"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200305000-00010"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22045"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/bms.1200130206"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01365"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4090"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14038"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-021-00061-5"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.21.1876"},{"key":"e_1_2_11_107_1","first-page":"1185","article-title":"[3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line","volume":"288","author":"Hammond J.R.","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2131"},{"key":"e_1_2_11_109_1","first-page":"4349","article-title":"Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines","volume":"58","author":"Mackey J.R.","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.067"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.06.012"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0224"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013133415945"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.3.491"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685109"},{"key":"e_1_2_11_116_1","first-page":"1501","article-title":"The pharmacokinetics and long\u2010term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation","volume":"39","author":"Hirano S.","year":"2012","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2004.00543.x"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544110-00004"},{"key":"e_1_2_11_119_1","unstructured":"US Food and Drug Administration.Iressa (Gefitinib) Clinical Pharmacology and BioPharmaceutics Review(s)<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206995orig1s000clinpharmr.pdf> (2014). Accessed February 5 2023."},{"key":"e_1_2_11_120_1","unstructured":"Caprelsa (Vandetanib) Clinical Pharmacology and BioPharmaceutics Review(s). U.S. Food and Drug Administration <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022405Orig1s000ClinPharmR.pdf> (2010). Accessed February 5 2023."},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.001"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30084-0"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.128127"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.067"},{"key":"e_1_2_11_125_1","unstructured":"US Food and Drug Administration.Coronavirus (COVID\u201019) update: FDA authorizes first oral antiviral for treatment of COVID\u201019<https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/coronavirus\u2010covid\u201019\u2010update\u2010fda\u2010authorizes\u2010first\u2010oral\u2010antiviral\u2010treatment\u2010covid\u201019> (2021). Accessed February 5 2023."},{"key":"e_1_2_11_126_1","unstructured":"US Food and Drug Administration.Coronavirus (COVID\u201019) update: FDA authorizes additional oral antiviral for treatment of COVID\u201019 in certain adults<https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/coronavirus\u2010covid\u201019\u2010update\u2010fda\u2010authorizes\u2010additional\u2010oral\u2010antiviral\u2010treatment\u2010covid\u201019\u2010certain> (2021). Accessed February 5 2023."},{"key":"e_1_2_11_127_1","unstructured":"US Food and Drug Administration.Lagevrio (molnupiravir) emergency use authorization review<https:\/\/www.fda.gov\/media\/155241\/download> (2021). Accessed February 5 2023."},{"key":"e_1_2_11_128_1","unstructured":"US Food and Drug Administration.Veklury (remdesivir) summary review<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214787Orig1s000Sumr.pdf> (2020). Accessed February 5 2023."},{"key":"e_1_2_11_129_1","unstructured":"US Food and Drug Administration.Veklury (remdesivir) EUA fact sheet for healthcare providers<https:\/\/www.fda.gov\/media\/137566\/download> (2022). Accessed February 5 2023."},{"key":"e_1_2_11_130_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13030369"},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-00984-5"},{"key":"e_1_2_11_132_1","unstructured":"US Food and Drug Administration.Lagevrio (molnupiravir) EUA fact sheet for healthcare providers<https:\/\/www.fda.gov\/media\/155054\/download> (2022) Accessed February 5 2023."},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_2_11_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184"},{"key":"e_1_2_11_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.050"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2020.1858234"},{"key":"e_1_2_11_139_1","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00022.2009"},{"key":"e_1_2_11_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2021.101000"},{"key":"e_1_2_11_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105180"},{"key":"e_1_2_11_142_1","volume-title":"Review of the Fialuridine (FIAU) Clinical Trials","author":"Institute of Medicine (US) Committee to Review the Fialuridine (FIAU\/FIAC) Clinical Trials","year":"1995"},{"key":"e_1_2_11_143_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510263331702"},{"key":"e_1_2_11_144_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.25.12003"},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2134"},{"key":"e_1_2_11_146_1","unstructured":"US Food and Drug Administration.Clolar (clofarabine) prescribing information<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021673s023lbl.pdf> (2014) Accessed February 5 2023."},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22959"},{"key":"e_1_2_11_148_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.11.1857"},{"key":"e_1_2_11_149_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.922"},{"key":"e_1_2_11_150_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124602"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T04:36:14Z","timestamp":1704170174000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1002\/cpt.2984"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2984","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"2023-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}